Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090857 · ClinicalTrials.gov registry record · Phase 2
Letrozole in Preventing Breast Cancer in Postmenopausal Women
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00090857 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 49 participants.
The verdict
NCT00090857, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Letrozole may be effective in preventing the development or recurrence of breast cancer in postmenopausal women who are at increased risk of developing breast cancer because of elevated estradiol levels. PURPOSE: This randomized phase II trial is studying how well letrozole works in preventing breast cancer in postmenopausal women with elevated estradiol levels.
Interventions
- OTHER Placebo
- DRUG Letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2002-02 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090857
The ClinicalTrials.gov registry entry for NCT00090857 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00090857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090857 about?
NCT00090857 is a clinical study titled "Letrozole in Preventing Breast Cancer in Postmenopausal Women". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Letrozole may be effective in preventing the development or recurrence of breast cancer in postmenopausal women who are at increased risk of developing breast cancer because of e...
What is the current status of trial NCT00090857?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2002-02. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00090857?
The interventions under investigation include: Placebo (OTHER), Letrozole (DRUG).
Who is sponsoring clinical trial NCT00090857?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.